mirtazapine has been researched along with Amentia in 11 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On cost-effectiveness grounds, the use of mirtazapine cannot be recommended for agitated behaviors in people living with dementia." | 9.51 | Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fountain, J; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, JT; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2022) |
| "This parallel-group, double-blind, placebo-controlled trial-the Study of Mirtazapine for Agitated Behaviours in Dementia trial (SYMBAD)-was done in 26 UK centres." | 9.41 | Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, J; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2021) |
| " Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable." | 9.30 | Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019) |
| " (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia." | 9.17 | Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia." | 9.17 | Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "On cost-effectiveness grounds, the use of mirtazapine cannot be recommended for agitated behaviors in people living with dementia." | 5.51 | Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fountain, J; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, JT; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2022) |
| "This parallel-group, double-blind, placebo-controlled trial-the Study of Mirtazapine for Agitated Behaviours in Dementia trial (SYMBAD)-was done in 26 UK centres." | 5.41 | Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, J; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2021) |
| " Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable." | 5.30 | Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019) |
| " (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia." | 5.17 | Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia." | 5.17 | Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia." | 2.45 | Non-pharmacologic treatment of insomnia in persons with dementia. ( Darvishi, R; Kunik, ME; Shub, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Lanctôt, KL | 1 |
| Herrmann, N | 1 |
| Banerjee, S | 6 |
| High, J | 2 |
| Stirling, S | 2 |
| Shepstone, L | 2 |
| Swart, AM | 2 |
| Telling, T | 2 |
| Henderson, C | 2 |
| Ballard, C | 5 |
| Bentham, P | 5 |
| Burns, A | 5 |
| Farina, N | 2 |
| Fox, C | 5 |
| Francis, P | 2 |
| Howard, R | 2 |
| Knapp, M | 5 |
| Leroi, I | 2 |
| Livingston, G | 5 |
| Nilforooshan, R | 2 |
| Nurock, S | 5 |
| O'Brien, J | 4 |
| Price, A | 2 |
| Thomas, AJ | 2 |
| Tabet, N | 2 |
| Fountain, J | 1 |
| O'Brien, JT | 1 |
| Zuidersma, M | 1 |
| Chua, KC | 1 |
| Hellier, J | 4 |
| Voshaar, RO | 1 |
| Almeida, OP | 1 |
| Romeo, R | 3 |
| Dewey, M | 3 |
| Baldwin, R | 3 |
| Holmes, C | 3 |
| Katona, C | 3 |
| Lawton, C | 3 |
| Lindesay, J | 3 |
| McCrae, N | 3 |
| Moniz-Cook, E | 3 |
| Murray, J | 3 |
| Orrell, M | 2 |
| Poppe, M | 3 |
| Thomas, A | 3 |
| Walwyn, R | 3 |
| Wilson, K | 3 |
| Shub, D | 1 |
| Darvishi, R | 1 |
| Kunik, ME | 1 |
| Brodaty, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pragmatic, Multi Centre, Double-blind, Placebo Controlled Randomised Trial to Assess the Safety, Clinical and Cost Effectiveness of Mirtazapine in Patients With Alzheimer's Disease (AD) and Agitated Behaviours[NCT03031184] | Phase 3 | 207 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mirtazapine and Amentia
| Article | Year |
|---|---|
Non-pharmacologic treatment of insomnia in persons with dementia.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antidepressive Agents, Tricyclic; Circadian Rhyth | 2009 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
7 trials available for mirtazapine and Amentia
| Article | Year |
|---|---|
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
Topics: Aged, 80 and over; Anti-Anxiety Agents; Brief Psychiatric Rating Scale; Caregivers; Dementia; Double | 2021 |
No benefit from mirtazapine for treating agitation in dementia.
Topics: Dementia; Double-Blind Method; Humans; Mirtazapine | 2022 |
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial.
Topics: Caregivers; Cost-Benefit Analysis; Dementia; Humans; Mirtazapine; Quality of Life | 2022 |
Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depression; Double-Blin | 2019 |
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Dementia; Depr | 2013 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.
Topics: Antidepressive Agents; Caregivers; Cost-Benefit Analysis; Dementia; Depression; Health Care Costs; H | 2013 |
3 other studies available for mirtazapine and Amentia
| Article | Year |
|---|---|
Mirtazapine for agitation in dementia: moving forward.
Topics: Antidepressive Agents; Dementia; Humans; Mianserin; Mirtazapine | 2021 |
The Challenge of Treating Depression in Dementia.
Topics: Dementia; Depression; Humans; Mirtazapine; Sertraline; Technology Assessment, Biomedical | 2019 |
Antidepressant treatment in Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Double-B | 2011 |